

## Food and Drug Administration, HHS

## § 349.3

- (ii) "Avoid contact with the eyes."
- (iii) "If you or your partner develop a rash or irritation, such as burning or itching, discontinue use. If symptoms persist, consult a doctor."

(2) [Reserved]

(d) *Directions*. The labeling of the product contains the following information under the heading "Directions":

(1) *For products containing any ingredient identified in § 348.10(a)—(i) For products containing benzocaine identified in § 348.10(a)(1)*. "Apply a small amount to head and shaft of penis before intercourse, or use as directed by a doctor. Wash product off after intercourse."

(ii) *For products containing lidocaine identified in § 348.10(a)(2)*. "Apply 3 or more sprays, not to exceed 10, to head and shaft of penis before intercourse, or use as directed by a doctor. Wash product off after intercourse."

(2) [Reserved]

(e) The word "physician" may be substituted for the word "doctor" in any of the labeling statements in this section.

## PART 349—OPHTHALMIC DRUG PRODUCTS FOR OVER-THE-COUNTER HUMAN USE

### Subpart A—General Provisions

Sec.

349.1 Scope.

349.3 Definitions.

### Subpart B—Active Ingredients

349.10 Ophthalmic astringent.

349.12 Ophthalmic demulcents.

349.14 Ophthalmic emollients.

349.16 Ophthalmic hypertonicity agent.

349.18 Ophthalmic vasoconstrictors.

349.20 Eyewashes.

349.30 Permitted combinations of active ingredients.

### Subpart C—Labeling

349.50 Labeling of ophthalmic drug products.

349.55 Labeling of ophthalmic astringent drug products.

349.60 Labeling of ophthalmic demulcent drug products.

349.65 Labeling of ophthalmic emollient drug products.

349.70 Labeling of ophthalmic hypertonicity drug products.

349.75 Labeling of ophthalmic vasoconstrictor drug products.

349.78 Labeling of eyewash drug products.

349.79 Labeling of permitted combinations of active ingredients.

349.80 Professional labeling.

AUTHORITY: 21 U.S.C. 321, 351, 352, 353, 355, 360, 371.

SOURCE: 53 FR 7090, Mar. 4, 1988, unless otherwise noted.

## Subpart A—General Provisions

### § 349.1 Scope.

(a) An over-the-counter ophthalmic drug product in a form suitable for topical administration is generally recognized as safe and effective and is not misbranded if it meets each of the conditions in this part and each of the general conditions established in § 330.1.

(b) References in this part to regulatory sections of the Code of Federal Regulations are to chapter I of title 21 unless otherwise noted.

### § 349.3 Definitions.

As used in this part:

(a) *Ophthalmic drug product*. A drug product, which should be sterile in accordance with § 200.50, to be applied to the eyelid or instilled in the eye.

(b) *Astringent*. A locally acting pharmacologic agent which, by precipitating protein, helps to clear mucus from the outer surface of the eye.

(c) *Buffering agent*. A substance which stabilizes the pH of solutions against changes produced by introduction of acids or bases from such sources as drugs, body fluids, tears, etc.

(d) *Demulcent*. An agent, usually a water-soluble polymer, which is applied topically to the eye to protect and lubricate mucous membrane surfaces and relieve dryness and irritation.

(e) *Emollient*. An agent, usually a fat or oil, which is applied locally to eyelids to protect or soften tissues and to prevent drying and cracking.

(f) *Eyewash, eye lotion, irrigating solution*. A sterile aqueous solution intended for washing, bathing, or flushing the eye.

(g) *Hypertonicity agent*. An agent which exerts an osmotic gradient greater than that present in body tissues and fluids, so that water is drawn

from the body tissues and fluids across semipermeable membranes. Applied topically to the eye, a hypertonicity agent creates an osmotic gradient which draws water out of the cornea.

(h) *Isotonicity*. A state or quality in which the osmotic pressure in two fluids is equal.

(i) *Vasoconstrictor*. A pharmacologic agent which, when applied topically to the mucous membranes of the eye, causes transient constriction of conjunctival blood vessels.

### Subpart B—Active Ingredients

#### § 349.10 Ophthalmic astringent.

The active ingredient and its concentration in the product is as follows: Zinc sulfate, 0.25 percent.

#### § 349.12 Ophthalmic demulcents.

The active ingredients of the product consist of any of the following, within the established concentrations for each ingredient:

- (a) Cellulose derivatives:
  - (1) Carboxymethylcellulose sodium, 0.2 to 2.5 percent.
  - (2) Hydroxyethyl cellulose, 0.2 to 2.5 percent.
  - (3) Hydroxypropyl methylcellulose, 0.2 to 2.5 percent.
  - (4) Methylcellulose, 0.2 to 2.5 percent.
- (b) Dextran 70, 0.1 percent when used with another polymeric demulcent agent in this section.
- (c) Gelatin, 0.01 percent.
- (d) Polyols, liquid:
  - (1) Glycerin, 0.2 to 1 percent.
  - (2) Polyethylene glycol 300, 0.2 to 1 percent.
  - (3) Polyethylene glycol 400, 0.2 to 1 percent.
  - (4) Polysorbate 80, 0.2 to 1 percent.
  - (5) Propylene glycol, 0.2 to 1 percent.
  - (e) Polyvinyl alcohol, 0.1 to 4 percent.
  - (f) Povidone, 0.1 to 2 percent.

#### § 349.14 Ophthalmic emollients.

The active ingredients of the product consist of any of the following:

- (a) Lanolin preparations:
  - (1) Anhydrous lanolin, 1 to 10 percent in combination with one or more oleaginous emollient agents included in the monograph.
  - (2) Lanolin, 1 to 10 percent in combination with one or more oleaginous

emollient agents included in the monograph.

(b) Oleaginous ingredients:

- (1) Light mineral oil, up to 50 percent in combination with one or more other emollient agents included in the monograph.
- (2) Mineral oil, up to 50 percent in combination with one or more other emollient agents included in the monograph.
- (3) Paraffin, up to 5 percent in combination with one or more other emollient agents included in the monograph.
- (4) Petrolatum, up to 100 percent.
- (5) White ointment, up to 100 percent.
- (6) White petrolatum, up to 100 percent.
- (7) White wax, up to 5 percent in combination with one or more other emollient agents included in the monograph.
- (8) Yellow wax, up to 5 percent in combination with one or more other emollient agents included in the monograph.

#### § 349.16 Ophthalmic hypertonicity agent.

The active ingredient and its concentration in the product is as follows: Sodium chloride, 2 to 5 percent.

#### § 349.18 Ophthalmic vasoconstrictors.

The active ingredient of the product consists of one of the following, within the established concentration for each ingredient:

- (a) Ephedrine hydrochloride, 0.123 percent.
- (b) Naphazoline hydrochloride, 0.01 to 0.03 percent.
- (c) Phenylephrine hydrochloride, 0.08 to 0.2 percent.
- (d) Tetrahydrozoline hydrochloride, 0.01 to 0.05 percent.

#### § 349.20 Eyewashes.

These products contain water, tonicity agents to establish isotonicity with tears, agents for establishing pH and buffering to achieve the same pH as tears, and a suitable preservative agent.